Shares of OncoSec Medical Inc (NASDAQ:ONCS) have been assigned a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $5.33.
A number of analysts have recently weighed in on the stock. Piper Jaffray Companies assumed coverage on shares of OncoSec Medical in a research report on Friday. They issued an “overweight” rating on the stock. ValuEngine raised shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 9th. HC Wainwright set a $6.00 target price on shares of OncoSec Medical and gave the stock a “buy” rating in a research report on Friday, January 19th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $5.00 target price on shares of OncoSec Medical in a research report on Thursday, October 26th.
Shares of OncoSec Medical (NASDAQ:ONCS) opened at $1.70 on Friday. The firm has a market cap of $58.25, a PE ratio of -1.59 and a beta of 3.37. OncoSec Medical has a 1 year low of $0.88 and a 1 year high of $2.95.
In other news, CEO Daniel J. O’connor purchased 16,667 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The shares were bought at an average price of $1.50 per share, for a total transaction of $25,000.50. Following the purchase, the chief executive officer now directly owns 16,667 shares in the company, valued at approximately $25,000.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 5.50% of the company’s stock.
WARNING: “OncoSec Medical Inc (ONCS) Receives Consensus Rating of “Buy” from Brokerages” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/16/oncosec-medical-inc-oncs-receives-consensus-rating-of-buy-from-brokerages.html.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.